Screener
Spyre Therapeutics, Inc. SYRE Business Segments — Stock-Based Comp
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Compensation | $11,443 | $6,991 |
| Stock-based compensation (1) | 12,806 | 8,859 |
| Research and development, excluding compensation and stock-based compensation (2) (3) | 46,893 | 33,551 |
| Other segment items (4) (5) | (2,137) | (4,628) |
| Segment net loss | $69,005 | $44,773 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s business segments — stock-based comp?
- Spyre Therapeutics, Inc. (SYRE) reported business segments — stock-based comp of $12.81M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s business segments — stock-based comp changed year-over-year?
- Spyre Therapeutics, Inc.'s business segments — stock-based comp increased by 44.6% year-over-year, from $8.86M to $12.81M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s business segments — stock-based comp?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s business segments — stock-based comp has grown at a 74.2% compound annual growth rate (CAGR), from $7.11M to $37.61M.
- What does business segments — stock-based comp mean?
- The non-cash expense recognized for equity-based awards granted to employees and directors within the segment. It serves as a tool for talent retention and alignment of interests between staff and shareholders.
Ask your AI about Spyre Therapeutics, Inc.'s business segments — stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude